文献速递浆细胞疾病

靶向Otub1/c-Maf轴治疗多发性骨髓瘤

Targeting the Otub1/c-Maf axis for the treatment of multiple myeloma.
PubMed 文献 · Blood · 2021-01-01

本研究通过质谱发现去泛素化酶Otub1与c-Maf相互作用,Otub1去除c-Maf的K48链接多泛素化从而阻止其降解并增强转录活性。通过c-Maf识别元件驱动的荧光素酶筛选FDA批准药物和天然产物,发现洋地黄糖苷毛花苷C(LanC)可破坏Otub1与c-Maf的相互作用,诱导c-Maf降解并抑制骨髓瘤生长。

要点

  • Otub1是c-Maf的新型去泛素化酶,通过Lys71和N端依赖、UBE2O非依赖方式去除c-Maf的K48多泛素化。
  • 沉默Otub1导致c-Maf降解并诱导表达c-Maf的骨髓瘤细胞凋亡。
  • 毛花苷C(LanC)破坏Otub1与c-Maf相互作用,诱导c-Maf降解并抑制骨髓瘤生长。

核心结论

  • Otub1/c-Maf轴是多发性骨髓瘤的潜在治疗靶点。
  • 毛花苷C通过破坏Otub1与c-Maf相互作用诱导c-Maf降解,抑制骨髓瘤生长并延长模型小鼠总生存期,无明显毒性。

研究设计与样本

  • 基础研究:通过质谱鉴定Otub1与c-Maf相互作用,并采用c-Maf识别元件驱动的荧光素酶报告系统对FDA批准药物和天然产物进行筛选。

主要发现

  • Otub1与c-Maf相互作用,去除c-Maf的K48链接多泛素化,阻止其降解并增强转录活性;该去泛素化活性依赖其Lys71和N端,但不依赖已知c-Maf的E2酶UBE2O。
  • Otub1促进骨髓瘤细胞存活和骨髓瘤肿瘤生长;沉默Otub1导致c-Maf降解并诱导表达c-Maf的骨髓瘤细胞凋亡。
  • 毛花苷C(LanC)可阻止c-Maf去泛素化并通过破坏Otub1与c-Maf的相互作用诱导其降解。
  • 毛花苷C抑制c-Maf转录活性,诱导表达c-Maf的骨髓瘤细胞凋亡,抑制骨髓瘤生长并延长模型小鼠总生存期,无明显毒性。

关键数值与推荐

  • Otub1的去泛素化活性依赖其Lys71和N端,不依赖UBE2O。
  • 毛花苷C通过破坏Otub1与c-Maf相互作用阻止c-Maf去泛素化并诱导其降解。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The oncogenic transcription factor c-Maf has been proposed as an ideal therapeutic target for multiple myeloma (MM), but how to achieve it is still elusive. In the present study, we found the Otub1/c-Maf axis could be a potential target. Otub1, an OTU family deubiquitinase, was found to interact with c-Maf by mass spectrometry. Otub1 abrogates c-Maf K48-linked polyubiquitination, thus preventing its degradation and enhancing its transcriptional activity. Specifically, this deubiquitinating activity depends on its Lys71 and the N terminus but is independent of UBE2O, a known E2 of c-Maf. Otub1 promotes MM cell survival and MM tumor growth. In contrast, silence of Otub1 leads to c-Maf degradation and c-Maf-expressing MM cell apoptosis. Therefore, the Otub1/c-Maf axis could be a therapeutic target of MM. In order to explore this concept, we performed a c-Maf recognition element-driven luciferase-based screen against US Food and Drug Administration-approved drugs and natural products, from which the generic cardiac glycoside lanatoside C (LanC) is found to prevent c-Maf deubiquitination and induces its degradation by disrupting the interaction of Otub1 and c-Maf. Consequently, LanC inhibits c-Maf transcriptional activity, induces c-Maf-expressing MM cell apoptosis, and suppresses MM growth and prolongs overall survival of model mice, but without apparent toxicity. Therefore, the present study identifies Otub1 as a novel deubiquitinase of c-Maf and establishes that the Otub1/c-Maf axis is a potential therapeutic target for MM.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Xu Y, Xu M, Tong J, et al. Targeting the Otub1/c-Maf axis for the treatment of multiple myeloma. Blood. 2021. PMID: 32842143. doi:10.1182/blood.2020005199

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。